ClinicalTrials.gg
CompletedNCT00931905Updated Aug 3, 2009

Homeopathic Preparation Plumbum Metallicum for Lead Poisoning

A Phase 4 interventional study of Homeopathic medication Plumbum metallicum and Hydroalcoholic solution in Lead Poisoning, sponsored by Federal University of São Paulo. Completed at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-08-03.

Sponsored by Federal University of São Paulo · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Saturnism, or lead poisoning, is defined by clinical symptoms (affecting primarily the nervous, hematopoietic, gastrointestinal, cardiovascular, musculoskeletal, renal and reproductive systems) compatible with exposure, in the short or long term, to lead or to its compounds, and can manifest as acute or chronic symptoms, pursuant to the intensity and duration of the signs and symptoms. Measuring serum concentration is the primary method for diagnosing and accompanying exposed workers. Presently, elevated lead counts are reversed by using drugs whose effectiveness is contested on various fronts. Experimental studies shows the efficacy of homeopathic preparations in controlling blood lead levels in laboratory animals, creating the need for controlled studies that evaluate the effectiveness and safety of these preparations in humans.The objective of this study was evaluate the effectiveness of the homeopathic preparation Plumbum metallicum in reducing the blood lead level of workers exposed to this metal.

02

Conditions studied

  • Lead Poisoning

Browse trials for

Keywords

  • This study included workers exposed to lead.
03

In context

Lead Poisoning

27 studies on the registry are indexed under Lead Poisoning; 2 are open to participants now.

This study's enrollment of 113 is below the median of 175 across 11 interventional studies indexed under Lead Poisoning.

Browse Lead Poisoning studies →

Lead sponsor

Federal University of São Paulo is the lead sponsor of 439 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • had not taken a leave of absence for any reason for a period greater than seven days in the 60 days prior to the intervention;
  • where in good medical condition, as analyzed by their medical records and physical exam;
  • had an initial blood lead level less than the maximum biological concentration permitted, which is 60µ/dL in Brazil.

Exclusion criteria

Exclusion Criteria:

  • workers who, in the last six months, had used medication that interferes/d with the level of lead in the blood, such as EDTA, BAL, penicillinase and DMSA;
  • workers who had the right to vacation during the study period;
  • workers who did not give their consent to participate in the study.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
113 participants

Study arms

  • Experimental
    Homeopathic medication Plumbum metallicum

    The homeopathic medication Plumbum metallicum 15CH was used, and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.

    Drug: Homeopathic medication Plumbum metallicum

  • Placebo comparator
    hydroalcoholic solution

    The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol.

    Other: Hydroalcoholic solution

Interventions

  • DrugHomeopathic medication Plumbum metallicum

    The homeopathic medication Plumbum metallicum 15CH was used and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.The drugs were administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.

  • OtherHydroalcoholic solution

    The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol. It was administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.

06

What researchers measure

Primary outcomes

  1. Effectiveness of the homeopathic preparation Plumbum metallicum in treating poisoning with respect to the decrease of the blood lead level of workers exposed to lead.

07

Study locations

1 site
  • Universidade Federal de Sao Paulo
    Sao Paulo, 04039-001, Brazil
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 3, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00931905
First posted
Jul 2, 2009
Last update
Aug 3, 2009

Study contacts

Roberto Q Padilha, MD
principal investigator · Federal University of São Paulo
Rachel Riera, MD
study chair · Federal University of São Paulo
Alvaro N Atallah, phD
study director · Federal University of São Paulo

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion